DC
SLS icon

Diametric Capital’s SELLAS Life Sciences SLS Stock Holding History

Diametric Capital’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-160,194
Closed -$200K – 435
2024
Q3 		$200K Buy
160,194
+7,175
+5% +$8.77K 0.1% 307
2024
Q2 		$182K Buy
+153,019
New +$208K 0.1% 281

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Diametric Capital's SLS Position: Q4 2024 in Review

Diametric Capital sold out of SELLAS Life Sciences (SLS) in Q4 2024, closing a stake of 160,194 shares — an estimated $200K sold.

Diametric Capital first reported a position in SLS in Q2 2024 and held it in 2 quarters. The position peaked at $200K in Q3 2024. 31 funds tracked by Wall St. Rank hold SLS as of Q4 2024.

  • Diametric Capital reported no remaining SELLAS Life Sciences position as of Q4 2024 after selling out during the quarter.
  • Diametric Capital sold 160,194 SELLAS Life Sciences shares in Q4 2024, an estimated $200K.
  • Diametric Capital first reported a position in SELLAS Life Sciences in Q2 2024 and held it in 2 quarters.
  • Diametric Capital's SELLAS Life Sciences position peaked at $200K in Q3 2024.
  • 31 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q4 2024.

Based on Diametric Capital's 13F filing for Q4 2024, filed 12 Feb 2025.